Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant improvements in progression-free survival (PFS) and response rates compared to the standard of care for women with certain types of breast and ovarian cancers. These studies were presented today in Barcelona as late-breaking abstracts at the European Society for Medical Oncology Congress 2019. As the...
Early results from two MD Anderson studies show promising responses to neoadjuvant (pre-surgical) checkpoint inhibitors in patients with advanced...
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer globally. Even with multimodality treatment, including surgery...
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits in new indications can be a challenging discovery process.
A team of researchers led by MD Anderson and the IRCCS Regina Elena National Cancer Institute in Rome have used a novel computer-aided drug discovery approach to identify decitabine, an FDA approved therapy for myelodysplastic...
MD Anderson researchers have developed the first machine learning algorithm to predict acute toxicities in patients receiving radiation therapy...
Multiple myeloma is the second most common hematological malignancy in the United States, and it’s increasing in incidence. An estimated 32,110...
A study from researchers at The University of Texas MD Anderson Cancer Center found that the prevalence of the types of oral human papillomavirus...
Small precancerous growths in the lungs are capable of progressing to invasive lung cancer, but so little has been known about them that understanding...